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Background: Rab27A is a peculiar member in Rab family and has been suggested to play essential roles in the
development of human cancers. However, the association between Rab27A expression and clinicopathological
characteristics of colorectal cancer (CRC) has not been elucidated yet.
Methods: One-step quantitative real-time polymerase chain reaction (qPCR) test with 18 fresh-frozen CRC samples
and immunohistochemistry (IHC) analysis in 112 CRC cases were executed to evaluate the relationship between
Rab27A expression and the clinicopathological features of CRC. Cox regression and Kaplan-Meier survival analyses
were performed to identify the prognostic factors for 112 CRC patients.
Results: The results specified that the expression levels of Rab27A mRNA and protein were significantly higher
in CRC tissues than that in matched non-cancerous tissues, in both qPCR test (p = 0.029) and IHC analysis
(p = 0.020). The IHC data indicated that the Rab27A protein expression in CRC was statistically correlated
with lymph node metastasis (p = 0.022) and TNM stage (p = 0.026). Cox multi-factor analysis and Kaplan-Meier
method suggested Rab27A protein expression (p = 0.012) and tumor differentiation (p = 0.004) were significantly
associated with the overall survival of CRC patients.
Conclusion: The data indicated the differentiate expression of Rab27A in CRC tissues and matched non-cancerous
tissues. Rab27A may be used as a valuable prognostic biomarker for CRC patients.
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Colorectal cancer (CRC) is the third most common
cancer and more than 1 million people develop CRC an-
nually [1]. It is reported that there are estimated 140,000
newly diagnosed cases of CRC and approximately 50,000
cancer deaths from CRC in America in 2013 [2, 3]. Of
patients with primary CRC, nearly 20 % encounter distant
metastasis at the time of diagnosis and only 10-30 % of
patients with distant metastasis can have potentially cura-
tive resection of the primary tumor and the distant focus
[4–6]. For CRC prognosis, survival is critically related to
stage at diagnosis, with five-year survival rates of 90 % for
localized cases, while 67 % for regional cases and only
10 % for distant metastatic cases [7]. Although the great* Correspondence: chenps@seu.edu.cn
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provided the original work is properly crediteddevelopments for diagnosis and treatment for CRC, the
overall survival rate of CRC patients rarely shows the
encouraging result and post-operative recurrence and
metastasis remain the two most challenging obstacles [8].
Hence it is valuable and necessary to identify molecular
predictive markers for the prognosis, which would facili-
tate the selection of therapeutic strategies and further
ameliorate patients’ survival for CRC [9].
The Rab family is a group of Ras-like small GTPases
which locates in specific subcellular organelle and plays
an important role in cell secretion, endocytosis, signal
transduction, and development [10–12]. Rab27A is a
peculiar member in Rab family for its specific role in hu-
man hereditary disease and dysfunction, such as Griscelli
syndrome [13, 14]. Recently, several studies reported the
diverse function of Rab27A in many kinds of human
cancers. Differential expression of Rab27A was detected
in murine xenografts of breast cancer (BC) metastasise distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
.
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metastatic potential of human BC cells [15]. Rab27A
enhanced various ability of glioma cell, such as develop-
ing proliferation, promoting invasion and inhibiting
apoptosis [16]. Rab27A also affected exosome secretion,
modified tumor microenvironment and finally promoted
tumor progression [17]. Moreover, two studies reported
the prognostic role of Rab27A that high Rab27A expres-
sion indicated poor survival of patients with gliomas and
hepatocellular carcinoma (HCC) [18, 19]. All the above
information suggest the significant relationship between
Rab27A and cancer while the performance of Rab27A in
CRC has yet to be explored. What function does Rab27A
play in CRC deveolopment and what is the relationship
between Rab27A expression and clinical features of
CRC? We conducted this present research.
In this retrospective study, the mRNA and protein
expression of Rab27A in CRC was investigated by one-
step quantitative real-time polymerase chain reaction
(qPCR) test and immunohistochemistry (IHC) analysis
respectively. Subsequently, the correlations of Rab27A
expression with the clinicopathological parameters of
CRC were further explored. Finally, the survival analysis
for identifying prognostic factors was executed.
Methods
Ethics statement
The Ethics Committee of the Affiliated Hospital of
Nantong University and each local hospital approved the
study protocol. A written informed consent and related
pictures were also acquired from each patient for publi-
cation of this present research.
CRC patient specimens
Formalin-fixed, paraffin-embedded tumor samples from
112 CRC cases and 113 matched non-cancerous tissue
specimens were collected in CRC patients from the
Department of Pathology, the Affiliated Hospital of
Nantong University from 2003 to 2008. Representative
and important clinical information were collected from
hospital medical records, including gender, age, tumor
size, tumor location, histological type, tumor differenti-
ation, serum carcino-embryonic antigen (CEA) level,
primary tumor (T), lymph node metastasis (N), distant
metastasis (M), as well as TNM stage which was classi-
fied using the 7th American Joint Committee on Cancer
(AJCC) staging system for CRC and overall survival
status [20]. None of the patients received radiotherapy,
chemotherapy, or immunotherapy prior to enterectomy.
One-step qPCR analysis
18 fresh CRC cancer tissue samples and 18 normal
tumor-adjacent tissue samples were collected from the
Department of Pathology, Affiliated Cancer Hospital ofNanjing Medical University for qPCR analysis. Total
RNA extraction, quality control, and one-step qPCR
analysis were performed as previously described [21, 22].
The primers for Rab27A were as follows: forward pri-
mer 5’- GTA AGT GAC ATA GTA GTT -3’ and reverse
primer 5’- TTA TTC GTA GGT CTA ATG -3’. The
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA level was employed to standardize the measure-
ments of the target gene and the primers for GAPDH
were as follows: forward primer 5’-TGC ACC ACC AAC
TGC TTA GC-3’ and reverse primer 3’-GGC ATG GAC
TGT GGT CAT GAG-5’. Amplification conditions con-
sisted of 30 min at 42 °C for reverse transcription and
2 min at 94 °C for Taq activation, followed by 35 cycles
at 95 °C for 20 s, 56 °C for 20 s, and elongation at 72 °C
for 30 s. Each measurement was performed in triplicate.
Tissue microarrays (TMA) construction and IHC analysis
112 CRC and 113 normal tumor-adjacent tissues were
enrolled in this present study. TMA was produced by
the Department of Pathology, the Affiliated Hospital of
Nantong University. Core tissue biopsies (2 mm in
diameter) were taken from individual paraffin-embedded
sections and arranged in the new recipient paraffin
blocks. TMA was cut into 4-μm sections and placed on
super frost charged glass microscope slides. IHC analysis
was performed as previously described [23–25]. Deparaf-
finized sections (4 μm thick) from array blocks were
separately stained on an Autostainer Universal Staining
System (LabVision, Kalamazoo, MI, USA) using mouse
anti-Rab27A antibody (1:100, Abcam, Cambridge, UK).
The secondary antibody used was horseradish peroxidase-
conjugated antibody (Dako Cytomation, Carpinteria, CA,
USA).
Rab27A immunostaining observation and evaluation
were simultaneously performed by two independent
pathologists. IHC results were analyzed according to a
previously described method [24, 26, 27]. Staining inten-
sity was scored as follows: 0 (negative), 1 (weakly posi-
tive), 2 (moderately positive), and 3 (strongly positive).
The percentage of Rab27A-positive cells was also classi-
fied into 4 categories, where 1 was given for 0-10 %, 2
for 11-50 %, 3 for 51-80 %, and 4 for 81-100 %. The
product of the intensity and percentage scores gave rise
to the final Rab27A staining score. The degree of Rab27A
staining was sorted by a two-level grading system, and
staining scores were described as follows: a score below 4
(<4) suggested low or no expression of Rab27A, while a
score above 4 (≥4) suggested high expression of Rab27A.
Statistical analysis
The Rab27A mRNA expression normalized to GAPDH
in CRC samples compared with matching non-cancerous
tissue samples was analyzed with the Wilcoxon non-
Table 1 Correlation of Rab27A expression with
clinicopathological characteristics of 112 CRC patients
Groups No. Rab27A χ2 p
value+ %
Gender 1.1835 0.277
Male 73 39 53.4
Female 39 25 64.1
Age (years) 0.0133 0.908
≥60 74 42 56.8
<60 38 22 57.9
Tumor size (cm) 0.4585 0.498
≥5 47 25 53.2
<5 62 37 59.7
Insufficient data 3 2
Tumor location 1.9870 0.370
Colon 57 32 56.1
Rectum 51 31 60.8
Ileocecal junction 4 1
Histological type 2.3425 0.126
Adenocarcinoma 102 56 54.9
Non-adenocarcinoma 10 8 80.0
Tumor differentiation 3.3634 0.186
Well 1 0 0.0
Moderately 92 55 59.8
Poorly 15 6 40.0
Insufficient data 4 3
Serum CEA level (ng/ml) 0.2855 0.593
≥15 14 7 50.0
<15 71 41 57.7
Insufficient data 27 16
T (Primary tumor) 3.0490 0.218
T1 7 6 85.7
T2 26 16 61.5
T3 79 42 53.2
N (Lymph node metastasis) 5.2438 0.022*
Positive 44 31 70.5
Negative 68 33 48.5
M (Distant metastasis) 0.6280 0.428
Positive 5 2 40.0
Negative 107 62 57.9
TNM stage 9.2855 0.026*
Stage I 29 18 62.1
Stage II 36 14 38.9
Stage III 42 30 71.4
Stage IV 5 2 40.0
*p < 0.05
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Rab27A expression and clinicopathologic itemss of CRC
were evaluated with χ2 tests. Survival curves were
performed with Kaplan-Meier method. Univariate and
multivariate Cox regression model were performed to
detect the prognostic elements. For all tests, the signifi-
cance level for statistical analysis was set at p < 0.05. All
data were analyzed using STATA Version 12.0 ((Stata
Corporation, College Station, TX, USA).
Results
Summarization of clinical data of 112 CRC patients
A total of 112 CRC cases were collected from 73 men
and 39 women and the representative clinical data are
summarized in Table 1. The mean age of all cases at the
time of surgery was 65.14 years. There were 47 cases
with tumor diameter ≥5 cm, 62 with tumor diameter
<5 cm. The tumor locations of 57 patients were in colon,
51 patients in rectum and 4 patients in ileocecal junc-
tion. The histological type of tumor in 102 cases was
adenocarcinoma, while the other 10 cases were identi-
fied as non-adenocarcinoma type. 1 patient encountered
a well-differentiated tumor, 92 suffered moderate tumor
differentiation, and 15 had poor tumor differentiation.
High serum CEA level (≥15 ng/ml) was observed in 14
cases, whereas low serum CEA level (<15 ng/ml) was
displayed in 71 cases. The number of patients with T1,
T2, T3 were 7, 26 and 79 respectively. Positive lymph
node metastasis was observed in 44 patients while
distant metastasis was noticed in 5 patients. According
to TNM staging system, 29 patients were in stages I, 36
patients were in stages II, 42 patients were in stages III,
whereas the remaining 5 patients were in stages IV.
Detection of Rab27A mRNA expression by qPCR test
Total RNA was extracted from 18 CRC tissues as well as
matched tumor adjacent tissues, and then subjected to
one-step qPCR to detect Rab27A mRNA expression.
When normalizing to GAPDH, the means of Rab27A
mRNA in CRC tissues and that of the corresponding
non-cancerous tissues were calculated as 3.32 ± 0.518
and 1.76 ± 0.444, respectively (t = 2.281, p = 0.029).
Rab27A expression in the CRC samples was nearly
1.89-fold higher than that in matched non-cancerous
tissues (Fig. 1).
Detection of Rab27A protein expression by IHC
High Rab27A expression was observed in 64 (57.1 %)
of the 112 CRC samples compared with 47 (41.6 %)
of 113 matched normal tumor-adjacent tissue sam-
ples. The difference was of statistically significance
(χ2 = 5.44, p = 0.020) according to the χ2 test analysis
and the data was agreeable with the previous qPCR
test in which high level of Rab27A mRNA expression
Fig. 1 One-step quantitative real-time polymerase chain reaction
(qPCR) was employed to evaluate Rab27A mRNA expression levels
in 18 colorectal cancer (CRC) tissues compared with matched non-
cancerous tissues. When normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA levels, the Rab27A mRNA level in
CRC tissues (3.32 ± 0.518) is significantly higher than that in
corresponding non-cancerous tissues (1.76 ± 0.444)
Fig. 2 Representative images of Rab27A protein expression in colorectal ca
microarray (TMA) by immunohistochemistry (IHC) analysis. A1, A2 and A3 H
and B3 High IHC staining of Rab27A protein in nucleus of CRC cells. C1, C2
D3 High IHC staining of Rab27A protein in non-cancerous cells. E1, E2 and
magnification × 40 in A1, B1, C1, D1 and E1; ×200 in A2, B2, C2, D2 and E2;
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staining was mainly localized in the cytoplasm and
nucleus of CRC cells.
Association between Rab27A protein expression and
clinicopathological items
The association between high Rab27A protein expres-
sion and representative clinicopathological items was
summarized in Table 1. High Rab27A protein expres-
sion was statistically related to N (p = 0.022) and
TNM stage (p = 0.026). Relatively, other clinical items,
such as gender, age, tumor size and location, histo-
logical type and tumor differentiation, serum CEA
level and N, were rarely correlated with high Rab27A
protein expression (Table 1).
Survival analysis
According to univariate analysis, several factors were
correlated with overall survival of 112 CRC patients, in-
cluding Rab27A protein expression (p = 0.001), tumor
differentiation (p = 0.001), serum CEA level (p = 0.006),
T (p = 0.004), M (p = 0.005) and TNM stage (p = 0.003).
Moreover, multivariate analysis was executed and the
results showed that Rab27A protein expression (p =
0.012) and tumor differentiation (p = 0.004) were twoncer (CRC) tissues and corresponding non-cancerous tissues with tissue
igh IHC staining of Rab27A protein in cytoplasm of CRC cells. B1, B2
and C3 No IHC staining of Rab27A protein in CRC cells. D1, D2 and
E3 No IHC staining of Rab27A protein in non-cancerous cells. Original
×400 in A3, B3, C3, D3 and E3
Table 2 Univariate and multivariate analysis of prognostic factors in 112 CRC patients for overall survival
Univariate analysis Multivariate analysis
HR p value 95 % CI HR p value 95 % CI
Rab27A protein expression
High versus Low or no 0.33 0.001* 0.181–0.616 0.36 0.012* 0.159–0.794
Gender
Male versus Female 1.43 0.277 0.750–2.726
Age (years)
≥60 versus <60 1.16 0.642 0.618–2.184
Tumor size (cm)
≥5 versus <5 1.21 0.537 0.659–2.224
Tumor location
Colon versus Rectum versus Ileocecal junction 1.49 0.131 0.888–2.495
Histological type
Adenocarcinoma versus Non-adenocarcinoma 2.40 0.227 0.581–9.903
Tumor differentiation
Well-Moderately versus Poorly 0.23 0.001* 0.117–0.449 0.30 0.004* 0.134–0.689
Serum CEA level (ng/ml)
≥15 versus <15 2.83 0.006* 1.356–5.894 1.64 0.228 0.735–3.639
T (Primary tumor)
T1 versus T2 versus T3 0.31 0.004* 0.140–0.692 0.70 0.566 0.201–2.406
N (Lymph node metastasis)
Positive versus Negative 1.41 0.257 0.780–2.533
M (Distant metastasis)
Positive versus Negative 4.35 0.005* 1.542–12.171 2.53 0.281 0.467–13.772
TNM stage
Stage I versus Stage II versus Stage III versus Stage IV 0.58 0.003* 0.403–0.829 0.68 0.281 0.333–1.375
*p < 0.05
Fig. 3 Survival analysis of 112 colorectal cancer (CRC) patients by Kaplan-Meier method. a Overall survival rate in patients with high Rab27A protein
expression (green line) was significantly higher than that in patients with low or no Rab27A expression (red line). b Overall survival rate in patients with
well-moderately differentiation of tumor (green line) was significantly higher than that in patients with poorly differentiation of tumor (red line)
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Kaplan-Meier survival curves in Fig. 3 further demon-
strated that CRC patients with high Rab27A protein
expression and well-moderately tumor differentiation
encountered significantly favorable survival time.
Discussion
Recently, the roles of several members of the Rab family
in human cancer have drawn great attention, including
Rab23 and Rab25 [28–30]. As for Rab27A, high expres-
sion of Rab27A promoted invasiveness and metastasis of
breast cancer cells by secretion of insulin-like growth
factor-II [14]. Rab27A modulated the tumor microenvir-
onment and facilitated tumor development by regulating
exocytosis of multivesicular endosomes and lead to exo-
some secretion [17]. For glioma, Rab27A acted as an
oncogenic factor and significantly associated with tumor
progression and poor prognosis in all grades of gliomas
[18]. Similarly, in HCC, Rab27A expression was closely
correlated with HCC progression and can be used as a
valuable prognostic indicator for HCC patients [19].
Hence it is rationale to presume that Rab27A also
performs in CRC and there are certain relationships
between Rab27A expression and certain clinical features
of CRC patients.
The results of qPCR test with small samples of CRC
showed that Rab27A expression in CRC samples was
statistically increased than that in non-cancerous tissues.
In the subsequent IHC analysis, the results were consist-
ent with the previous qPCR test and the protein expres-
sion of Rab27A in CRC TMA was also higher than that
in non-cancerous tissues. The data of differential expres-
sion of Rab27A in CRC in this present study was con-
sistent with the content of previous reports which stated
that expression of Rab27A was significant higher in
glioma and HCC [18, 19]. In addition, high Rab27A pro-
tein expression do correlated with certain substantial
clinical attributes, including N and TNM stage. The
above data agreed with previous researches and sup-
ported the promotive function of Rab27A in tumorigen-
esis [16, 18, 19].
In the survival analyses of our present study, univariate
analysis revealed that several substantial items correlated
with overall survival of 112 CRC patients. Multivariate
analysis further elucidated that Rab27A protein expres-
sion and tumor differentiation may identified as two
independent prognostic factors for CRC prognosis in
this present study. Thoroughly, Kaplan-Meier curve
indicated that CRC patients with high Rab27A expression
had a significantly better prognosis than that of patients
with low or no expression. The data of survival analysis
were in line with the previous study, which mentioned the
prognostic effect of Rab27A in GC and CRC (without pro-
viding the exact survival data) [19].So far, there are still some inconsistencies even contra-
dictories concerning the effects of Rab27A in human
cancers. Hendrix et al. reported no expression of
Rab27A was detected in breast cancer [31] while Dong
et al. reported that Rab27A expression was higher in
primary HCC than in matched adjacent tissue [19]. High
expression of Rab27A showed poor survival in gliomas
and HCC as well as suggested favorable survival in GC
and CRC simultaneously [18, 19]. In my view, these dis-
crepant findings indicate that Rab27A may have different
molecular mechanisms in different human cancer under
specific circumstances. For instance, the secretion of
exosome critically needs the present of Rab27A and the
functions of tumor exosomes were dual. For one thing,
exosomes could transfer tumor antigens to dendritic
cells for presentation of these antigens to T lymphocytes
[32]. For another, exosomes showed inhibitory functions
on effector immune responses as well as promoted
metastasis [33, 34]. The multiple activities of exosome
may explain the complicated function of Rab27A in
human cancer. Further researches that enroll larger can-
cer samples and elucidate the potential mechanisms of
Rab27A performance are of great importance to prove
our presumption.
In summary, to our best knowledge, this study was the
first to report on the differential expression of Rab27A
in CRC and our data indicated that Rab27A may be
identified as a prognostic biomarker in CRC patients.
Conclusions
In conclusion, this is the first report of the differential
expression of Rab27A in CRC. High Rab27A expression
was detected in CRC tissues, and that CRC patients with
elevated Rab27A expression were prone to suffer malig-
nant behaviors including positive N and advanced TNM
stage. Moreover, high expression of Rab27A suggested
favorable prognosis in CRC patients.
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